Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on European Global Times.
Press releases published on April 1, 2025
Societe Generale offer to purchase certain of its debt securities
GlobeNewswire
·
April 1, 2025
SOCIETE GENERALE OFFER TO PURCHASE CERTAIN OF ITS DEBT SECURITIES Press release Paris, April 1, 2025 NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN OR INTO OR TO ANY PERSON LOCATED OR RESIDENT IN ANY JURISDICTION WHERE OR TO WHOM IT IS UNLAWFUL TO RELEASE …
Société Générale lance une offre de rachat sur certains titres de dette
GlobeNewswire
·
April 1, 2025
SOCIÉTÉ GÉNÉRALE LANCE UNE OFFRE DE RACHAT SUR CERTAINS TITRES DE DETTE Communiqué de presse Paris, le 1 avril 2025 NON DESTINÉ À ÊTRE PUBLIÉ, DIFFUSÉ OU DISTRIBUÉ A TOUT INDIVIDU SITUÉ OU RÉSIDENT DANS UNE JURIDICTION OÙ OU À QUI IL EST ILLÉGAL DE PUBLIER …
Holding(s) in Company
GlobeNewswire
·
April 1, 2025
Reykjavík, April 01, 2025 (GLOBE NEWSWIRE) -- TR-1: Standard form for notification of major holdings NOTIFICATION OF MAJOR HOLDINGS (to be sent to the relevant issuer and to the FCA in Microsoft Word format if possible) 1a. Identity of the issuer or the …
Clene to Present at the Jones Healthcare and Technology Innovation Conference
GlobeNewswire
·
April 1, 2025
SALT LAKE CITY, April 01, 2025 (GLOBE NEWSWIRE) -- Clene Inc. (Nasdaq: CLNN) (along with its subsidiaries, “Clene”) and its wholly owned subsidiary, Clene Nanomedicine Inc., a late clinical-stage biopharmaceutical company focused on revolutionizing the …
Turbo Energy’s SUNBOX Home All-In-One Energy Storage System Meets U.S.’s Highest Standards for Safety, Reliability and Performance
GlobeNewswire
·
April 1, 2025
Company Granted UL Certifications After Undergoing U.S.’s Most Demanding Testing and Evaluation Processes Company Advances U.S. Market Launch with Planned Installations in Five States VALENCIA, Spain, April 01, 2025 (GLOBE NEWSWIRE) -- Turbo Energy, S.A. ( …
Cerevance Presents Topline Results from Phase 2 ASCEND Trial of Solengepras as Monotherapy Treatment for Early-Stage Parkinson’s Disease at AD/PD 2025
GlobeNewswire
·
April 1, 2025
Solengepras showed evidence of potential benefit in functional and non-motor symptoms versus placebo as measured by MDS-UPRDS Parts I, II, NMSS, and ESS, consistent with its novel non-dopaminergic mechanism of action This investigational treatment was …
Clearmind Launches its EDC System to Support its Phase I/II Clinical Trial of its MEAI-Based Treatment
GlobeNewswire
·
April 1, 2025
The clinical trial is designed to evaluate the safety, tolerability and efficacy of Clearmind’s innovative, psychedelic-derived, MEAI-based compound in individuals with alcohol addiction Vancouver, Canada, April 01, 2025 (GLOBE NEWSWIRE) -- Clearmind …
Mainz Biomed Reports 2024 Financial Results and Provides Corporate Update
GlobeNewswire
·
April 1, 2025
Lab network revenue increased by 33% year over year, reflecting strong demand for ColoAlert® in EuropeOperating loss decreased by 30% and net loss by 18%, driven by targeted cost reductions and a sharper strategic focusBERKELEY, Calif. and MAINZ, Germany, …
Mersana Therapeutics Announces Upcoming Oral Presentation of Emi-Le Clinical Data at European Society for Medical Oncology (ESMO) Breast Cancer 2025 Annual Congress
GlobeNewswire
·
April 1, 2025
CAMBRIDGE, Mass., April 01, 2025 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ: MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-drug conjugates (ADCs) targeting cancers in areas of …
XIMEA Reveals Medium Format Camera with 4.1" IMX811 Sensor: Highest Resolution - 245 Mpix
GlobeNewswire
·
April 1, 2025
MUENSTER, Germany, April 01, 2025 (GLOBE NEWSWIRE) -- XIMEA, the innovator of high-resolution cameras with a unique feature set, expands the xiX-XL family by introducing the currently highest resolution cameras using a backside illuminated Sony IMX811 …
Merus to Participate in a Fireside Chat at the 24th Annual Needham Virtual Healthcare Conference
GlobeNewswire
·
April 1, 2025
UTRECHT, The Netherlands and CAMBRIDGE, Mass., April 01, 2025 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS), an oncology company developing innovative, full-length multispecific antibodies and antibody drug conjugates (Biclonics®, Triclonics® and ADClonics …
Brera Holdings Board Advisor Giuseppe Rossi Honored with Emotional Football Farewell at Historic Stadio Artemio Franchi
GlobeNewswire
·
April 1, 2025
Brera Holdings sponsored the Pepito Day event, with Brera club logos pictured on the LED screens. Giuseppe Rossi, Brera board advisor, pictured in the center of the photograph Dublin, Ireland and Florence, Italy, April 01, 2025 (GLOBE NEWSWIRE) -- Brera …
Merus nimmt an Kamingespräch auf der 24. jährlichen Needham Virtual Healthcare Conference teil
GlobeNewswire
·
April 1, 2025
UTRECHT, Niederlande, und CAMBRIDGE, Massachusetts, April 01, 2025 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS), ein Unternehmen für klinische Onkologie, das innovative, multispezifische Antikörper in voller Länge und Antikörper-Wirkstoff-Konjugate ( …
Merus participera à une discussion informelle lors de la 24e conférence annuelle Needham Virtual Healthcare
GlobeNewswire
·
April 1, 2025
UTRECHT, Pays-Bas et CAMBRIDGE, État du Massachussets, 01 avr. 2025 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq : MRUS), entreprise spécialisée en oncologie développant des anticorps de pleine longueur multispécifiques et des conjugués anticorps-médicament …
Advanced Medical Balloons presents results from HYDRA-PMCF study of hygh-tec®, demonstrating high performance and safety
GlobeNewswire
·
April 1, 2025
HYDRA-PMCF-study evaluated hygh-tec®, a new polyurethane fecal management system hygh-tec® showed a high level of sealing performance (no leakage in 89.3%) and was safe to use (94.2% no signs of infection; GLOBIAD score = 0+1A) Full results will be …
Avalyn Completes Successful Phase 1 Clinical Trials of AP02, its Novel Inhaled Formulation of Nintedanib, Preparing for Phase 2 Development in Idiopathic Pulmonary Fibrosis
GlobeNewswire
·
April 1, 2025
Topline data from the single- and multiple-ascending dose studies confirmed safety and favorable tolerability profile of AP02 at all dose levels Full safety, tolerability, and pharmacokinetics data to be presented at the American Thoracic Society 2025 …
Qualigen seeks to enter the $10 Billion CABG market with non-binding MOU to acquire Marizyme
GlobeNewswire
·
April 1, 2025
CARLSBAD, Calif., April 01, 2025 (GLOBE NEWSWIRE) -- Qualigen Therapeutics, Inc. (NASDAQ: QLGN) (the “Company”) announced today they have entered a non-binding Memorandum of Understanding (MOU) to acquire Marizyme (OTC: MRZM). Qualigen and Marizyme have …
Skyharbour Partner Company Terra Clean Energy Completes Winter Drill Program with Encouraging Results and Prepares a Significant Summer Drill Program at the South Falcon East Uranium Project
GlobeNewswire
·
April 1, 2025
Vancouver, BC, April 01, 2025 (GLOBE NEWSWIRE) -- Skyharbour Resources Ltd. (TSX-V: SYH) (OTCQX: SYHBF) (Frankfurt: SC1P) (“Skyharbour” or the “Company”) is pleased to announce that partner company Terra Clean Energy Corp. (“Terra”, previously Tisdale …
Evaxion announces business update and full year 2024 financial results
GlobeNewswire
·
April 1, 2025
COPENHAGEN, Denmark, April 1, 2025 - Evaxion Biotech A/S (NASDAQ: EVAX) (“Evaxion”), a clinical-stage TechBio company specializing in developing AI-Immunology™ powered vaccines, provides business update and announces full year 2024 financial results. …
Context Therapeutics to Participate in Upcoming Investor Conferences
GlobeNewswire
·
April 1, 2025
PHILADELPHIA, April 01, 2025 (GLOBE NEWSWIRE) -- Context Therapeutics Inc. (“Context” or the “Company”) (Nasdaq: CNTX), a clinical-stage biopharmaceutical company advancing T cell engaging bispecific antibodies for solid tumors, today announced its …